Clovis Oncology Inc. (CLVS) announced after the bell Monday that it has entered into a clinical trial collaboration with GlaxoSmithKline (GSK) to evaluate a combination therapy targeting mutant epidermal growth factor receptor non-small cell lung cancer. The stock is now up 1.64 on 38K shares.
Clovis Oncology gradually declined for the majority of Monday's session and closed down by 1.56 at $53.33. The stock dropped to a 3-week low and slipped beneath its 200-day moving average.
For comments and feedback contact: editorial@rttnews.com
Business News